bl-4162a has been researched along with Cardiomyopathies* in 3 studies
1 review(s) available for bl-4162a and Cardiomyopathies
| Article | Year |
|---|---|
Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review.
Anagrelide is used worldwide to treat essential thrombocythemia (ET) by reducing platelet counts. Cardiomyopathy and heart failure (HF) are rare but serious complications associated with anagrelide use, although no cases were reported during Japanese Phase I to III studies. A 46-year-old, otherwise healthy, Japanese ET patient developed HF with reduced ejection fraction after 18 months of treatment with 1.0-3.5 mg of anagrelide daily. HF was stabilized with anagrelide withdrawal and guideline-directed HF therapy. The cardiac function returned to normal after six months. This case suggests that anagrelide can cause cardiomyopathy and HF in ET patients, regardless of nationality, comorbid cardiovascular conditions, or therapy duration. Topics: Cardiomyopathies; Heart Failure; Humans; Middle Aged; Platelet Aggregation Inhibitors; Thrombocythemia, Essential | 2022 |
2 other study(ies) available for bl-4162a and Cardiomyopathies
| Article | Year |
|---|---|
Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
A comprehensive database inquiry at our institutions identified 11 patients with echocardiogram-documented idiopathic cardiomyopathy that post-dated a diagnosis of either polycythemia vera or essential thrombocythemia. Anagrelide therapy was temporally associated with the particular complication in 6 patients, all of whom experienced symptomatic and/or objective improvement after drug discontinuation. Topics: Cardiomyopathies; Female; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential | 2004 |
Anagrelide-induced cardiomyopathy.
Anagrelide, a selective thrombocytopenic agent, is administered to treat a variety of hematologic disorders. Despite limited clinical experience with this drug, serious cardiovascular events, including congestive heart failure, have been reported. The proposed mechanism of cardiotoxicity is attributed to inhibition of phosphodiesterase, resulting in positive inotropic activity and vasodilation. A 48-year-old woman with polycythemia vera developed cardiotoxicity manifested by congestive heart failure and palpitations. It was suspected to be temporally related to titrating dosages of anagrelide. Topics: Cardiomyopathies; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines | 2000 |